22 January 2026 in JACC: Advances
Guidelines and consensus statements lack consistent management targets and ranges for low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) in older adults. The objectives of the study were to investigate the relationships of LDL-C and HDL-C with cardiovascular disease (CVD) risk in older adults and to identify optimal target ranges for their management. This study included 217,442 U.K. Biobank participants aged ≥60 years, free of CVD and cancer at baseline. Multivariable Cox regression models and restricted cubic splines were employed to estimate HRs and 95% CIs for the associations of LDL-C and HDL-C levels with CVD outcome. During follow-up, 26,756 CVDs and 2,726 CVD deaths occurred. LDL-C exhibited U-shaped relationships with both incident CVD and CVD mortality (minimal risk: 3.600-4.204 mmol/L). HDL-C showed an L-shaped association with incident CVD but a U-shaped association with CVD mortality (minimal risk: 1.421-1.699 mmol/L). Compared with the reference LDL-C group, the Q1 group had a 39% higher incident CVD risk (HR: 1.39; 95% CI: 1.32-1.47) and 27% higher CVD mortality risk (HR: 1.27; 95% CI: 1.08-1.48). Conversely, compared with the reference HDL-C group, the Q6 group was associated with a lower incident CVD (HR: 0.90; 95% CI: 0.84-0.97) and higher CVD mortality risk (HR: 1.24; 95% CI: 1.01-1.51). Notably, the CVD risk rose progressively with joint LDL-C and HDL-C risk tiers. U/L-shaped associations of LDL-C and HDL-C with CVD risk in older adults underscore the importance of maintaining lipids within an optimal range. This distinct "Goldilocks zone" is associated with minimized risk and highlights current guideline limitations.
17 November 2025 in International Journal of Surgery
Background: This study quantified age-, sex-, and geography-stratified trends in fatal and nonfatal burdens of early-onset pancreatic cancer (EOPC) across global populations, sociodemographic index (SDI) regions, and high-burden Asian countries from 1990 to 2021. Methods: We analyzed Global Burden of Disease (GBD) 2021 data to quantify trends in EOPC burden using three epidemiological measures: mortality, incidence, and disability-adjusted life years (DALYs). Joinpoint regression subsequently calculated average annual percentage changes in EOPC burden trajectories. Results: Globally in 2021, EOPC accounted for 31 531 new cases and 26 996 deaths. Analyses revealed a concerning upward trajectory in EOPC burden, with persistently high disease burden observed in high-SDI regions. Asia bore the highest global EOPC burden (2021), predominantly driven by East Asia where developing nations – particularly China and India – disproportionately contributed. Crucially, while global pancreatic cancer data identified high fasting plasma glucose (FPG) as the primary risk factor (surpassing smoking), this metabolic shift was not observed in EOPC. Moreover, EOPC risk escalates with advancing age and disproportionately affects older males, corresponding to significantly elevated disease burden in this demographic. Conclusions: Over recent decades, the burden of EOPC has escalated steadily, revealing striking demographic gradients, geographic disparities, and evolving risk profiles. These findings underscore an urgent imperative for precision public health interventions targeting high-risk populations. Timely implementation is critical to mitigate EOPC’s disproportionate burden across Asia and developing nations, ultimately reversing its global trajectory.